Japan "Must Improve Patent System"

18 June 1995

US officials have urged Japan to strengthen its patent system, claiming that US companies do not receive enough patent protection there. The officials, who spoke on condition of anonymity only, said Japanese regulatory officials and courts interpret patents so narrowly that this allows other companies to make products with only insignificant differences.

Last year, the USA and Japan agreed on a variety of ways each country should change its patent system to bring it more in line with the rest of the world. By July 1, Japan is to allow patent applications in English, and also limit a system under which secondary patents are granted in a way allowing competitors to conduct what would be, under other countries' patent laws, infringements of an original patent.

Japan will also speed up its examination and evaluation process, and, by january 1, 1996, put into place a system to issue rulings on patents within three years.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight